BioMarin CEO Speaks on Gene Therapy for Hemophilia at JP Morgan – Rare Disease Report
Rare Disease Report |
BioMarin CEO Speaks on Gene Therapy for Hemophilia at JP Morgan
Rare Disease Report At the annual J.P. Morgan Healthcare Conference in San Francisco, BioMarin Chief Executive Officer Jean-Jacques Bienaime spoke about the company's development of valoctocogene roxaparvovec, a gene therapy in development for the treatment of Hemophilia … |
